PRELUDE THERAPEUTICS INC's ticker is PRLD and the CUSIP is 74065P101. A total of 52 filers reported holding PRELUDE THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,576,762 | -31.2% | 510,279 | +0.2% | 0.00% | 0.0% |
Q2 2023 | $2,292,255 | -21.8% | 509,390 | -1.0% | 0.00% | 0.0% |
Q1 2023 | $2,932,924 | -5.7% | 514,548 | -0.1% | 0.00% | 0.0% |
Q4 2022 | $3,110,425 | -8.3% | 514,971 | +0.3% | 0.00% | 0.0% |
Q3 2022 | $3,393,000 | +35.8% | 513,293 | +7.3% | 0.00% | 0.0% |
Q2 2022 | $2,498,000 | -24.9% | 478,525 | -0.7% | 0.00% | 0.0% |
Q1 2022 | $3,327,000 | -43.0% | 482,119 | +2.8% | 0.00% | -50.0% |
Q4 2021 | $5,837,000 | -60.4% | 468,797 | -0.7% | 0.00% | -50.0% |
Q3 2021 | $14,758,000 | +37.4% | 472,246 | +25.9% | 0.00% | +33.3% |
Q2 2021 | $10,741,000 | -11.8% | 375,166 | +33.4% | 0.00% | -25.0% |
Q1 2021 | $12,183,000 | -40.1% | 281,164 | -1.1% | 0.00% | -42.9% |
Q4 2020 | $20,334,000 | +30.3% | 284,187 | -45.1% | 0.01% | +16.7% |
Q3 2020 | $15,608,000 | – | 518,011 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Orbimed Advisors | 10,039,691 | $66,362,000 | 1.23% |
Baker Brothers Advisors | 10,123,824 | $66,918,000 | 0.44% |
HHLR ADVISORS, LTD. | 583,333 | $3,856,000 | 0.10% |
CAXTON ASSOCIATES LP | 85,992 | $568,000 | 0.08% |
Virtus ETF Advisers LLC | 24,180 | $160,000 | 0.06% |
GSA CAPITAL PARTNERS LLP | 54,173 | $358,000 | 0.05% |
DENALI ADVISORS LLC | 8,200 | $54,000 | 0.03% |
PDT Partners, LLC | 12,641 | $84,000 | 0.01% |
UBS ASSET MANAGEMENT AMERICAS LLC | 2,402,595 | $15,881,153,000 | 0.01% |
BRIDGEWAY CAPITAL MANAGEMENT, LLC | 36,949 | $244,000 | 0.01% |